The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Eczema affects millions of Americans, and any number of environmental and health factors can trigger flare-ups. What should ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The unique feline dermatological cases veterinary professionals can see at the clinic, plus how to approach them ...

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to ...

Positive results were announced from the ECZTEND extension study of Adbry in atopic dermatitis who took part in a previous parent trial.

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Jersey City-based Organon has completed its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company ...

Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...